
Downloaded from: http://researchonline.lshtm.ac.uk/19805/

DOI:
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery (Review)

Sundaram V, Barsam A, Virgili G

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2010, Issue 7

http://www.thecochranelibrary.com

**THE COCHRANE COLLABORATION**

**WILEY**
# Table of Contents

- **Header** .................................................. 1
- **Abstract** .................................................. 1
- **Plain Language Summary** ................................. 2
- **Background** ............................................... 2
- **Objectives** ................................................ 3
- **Methods** ................................................... 3
- **Results** .................................................... 5
  - Figure 1 .................................................. 6
- **Discussion** ............................................... 7
- **Authors' Conclusions** .................................... 8
- **Acknowledgements** ........................................ 8
- **References** ............................................... 8
- **Characteristics of Studies** ............................... 10

Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery

Venki Sundaram¹, Allon Barsam², Gianni Virgili³

¹c/o Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical Medicine, London, UK. ²Moorfields Eye Hospital NHS Foundation Trust, London, UK. ³Department of Specialised Surgical Sciences, University of Florence, Florence, Italy

Contact address: Venki Sundaram, c/o Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. venkisundaram@hotmail.com.

Editorial group: Cochrane Eyes and Vision Group.
Review content assessed as up-to-date: 23 May 2010.


Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Proliferative vitreoretinopathy (PVR) is a significant cause of failure in retinal reattachment surgery. Various pharmacological agents have shown potential benefit in reducing postoperative PVR risk.

Objectives

This review aimed to compare the use of intravitreal low molecular weight heparin (LMWH) alone or with 5-Fluorouracil (5-FU) versus placebo, as an adjunct in the prevention of PVR following retinal reattachment surgery.

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2010, Issue 5), MEDLINE (January 1950 to May 2010), EMBASE (January 1980 to May 2010), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) and ClinicalTrials.gov (http://clinicaltrials.gov). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 24 May 2010.

Selection criteria

We only included randomised controlled trials (RCTs) that compared intravitreal LMWH alone or with 5-FU, versus placebo for the prevention of postoperative PVR in patients undergoing primary vitrectomy for rhegmatogenous retinal detachment repair.

Data collection and analysis

Two review authors independently assessed trial quality and extracted data. The review authors contacted study authors for additional information.
Main results

We included two RCTs (with a total of 789 participants) comparing LMWH with 5-FU infusion and placebo. However, we did not perform a meta-analysis because of significant heterogeneity between these studies. One study found a significant beneficial effect of LMWH with 5-FU in reducing postoperative PVR compared to placebo (RR: 0.48, 95% confidence interval: 0.25 to 0.92), in 174 patients who were viewed at high-risk of developing postoperative PVR. The other study included 615 unselected cases of rhegmatogenous retinal detachment and could not show a difference between LMWH with 5-FU infusion and placebo in reducing PVR rates (RR: 1.45, 95% confidence interval: 0.76 to 2.76).

Authors’ conclusions

Results from this review indicate that there is inconsistent evidence from two studies on patients at different risk of PVR on the effect of LMWH and 5-FU used during vitrectomy to prevent PVR. Future research should be conducted on high risk patients only, until a benefit is confirmed at least in this patient subgroup.

Plain Language Summary

Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery

Proliferative vitreoretinopathy (PVR) is a retinal scarring process which occurs following retinal detachment. It is a major cause of failure of retinal reattachment surgery and impairment of ultimate visual recovery. Low weight molecular heparin (LMWH) and 5-Fluorouracil (5-FU) are agents that can be used during surgery to potentially reduce the amount of PVR following surgery.

The two studies included in this review looked at using LMWH with 5-FU during retinal detachment repair to see if there was an effect of reducing PVR levels after surgery. One study focused on patients who are considered at high-risk of developing PVR after surgery because of pre-existing ocular features, and found beneficial effects of this treatment in this group. The other study looked at a wider group of patients and did not find a benefit in using this combination treatment, and in certain patients the treatment was associated with poorer vision. Due to the inconsistency of the evidence, until further data are available, future research on the use of LMWH with 5-FU should be conducted only in retinal detachment patients who are likely to develop considerable retinal scarring after surgery.

Background

Description of the condition

Proliferative vitreoretinopathy (PVR) is defined as the growth and contraction of cellular membranes within the vitreous cavity and on both sides of the retinal surfaces. It is an anomalous scarring process in retinal detachments (Rachal 1979; SSG 1992). The condition is the result of proliferation of glial and retinal pigment epithelial cells, both of which normally act as supporting cells for the retina. The retinal epithelial cells change their function to become fibroblast-like cells, normally involved in wound healing and scarring, with contractile properties. The resultant tissue fibrosis and contracture distorts the inner retina resulting in further re-detachment. A retinal detachment can be defined as a separation of the neurosensory retina from the underlying retinal pigment epithelium.

Retinal reattachment is achieved with one operation in 70.7% of cases, and after one or more operations in 97.5% of cases (Heimann 2006). Proliferative vitreoretinopathy is the most common cause of failed surgery for rhegmatogenous retinal detachment (Rachal 1979; SSG 1992). Rhegmatogenous retinal detachment can be defined as a retinal detachment occurring due to a retinal break or tear that allows the liquid vitreous to pass through the break and detach the retina. This is the most common type of detachment.

Description of the intervention

A high success rate in primary retinal detachment surgery remains the basis for the prevention of PVR. In cases that develop PVR,
and in others identified initially as high-risk, the use of adjunctive medical agents is potentially of value in increasing surgical success rates. There are a number of studies showing a potential benefit from a variety of pharmacological interventions, including retinoic acid (Araiz 1993; Campochiaro 1991; Fekrat 1995; Verstraeten 1992), dexamethasone (Hui 1993; Tano 1980; Tano 1981), colchicines (Kirmani 1983; Lemor 1986), paclitaxel (taxol) (Daniels 1990; van Bockxmeer 1985), daunorubicin (Wiedemann 1987; Wiedemann 1991), and 5-Fluorouracil (5-FU) with heparin (Asaria 2001; Kumar 2003).

How the intervention might work

Low molecular weight heparin (LMWH) has been shown to reduce postoperative fibrin after vitrectomy (Iverson 1991). Heparin binds to fibronectin and to a wide range of growth factors, including acidic and basic fibroblast growth factors and platelet-derived growth factors (Blumenkranz 1992). 5-FU inhibits DNA synthesis, inhibits fibroblast proliferation and has been effective in reducing rates of PVR in animal models (Blumenkranz 1984). 5-FU and LMWH have actions at different stages of the PVR process, and using these agents in conjunction may produce a synergistic effect.

Why it is important to do this review

Neither intravitreal LMWH nor 5-FU are in routine clinical use in retinal detachment procedures, and a systematic review may help to ascertain whether routine clinical use of such interventions are beneficial.

OBJECTIVES

To compare intravitreal LMWH alone or with 5-FU to placebo as an adjunct in the prevention of PVR following retinal reattachment surgery.

The null hypothesis is that there is no difference between intravitreal LMWH or 5-FU versus placebo as an adjunct for the prevention of PVR following retinal reattachment surgery.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs) only.

Types of participants

We included people who were aged 16 years or older and were undergoing primary vitrectomy surgery for rhegmatogenous retinal detachments. We excluded participants who had posterior penetrating trauma, proliferative diabetic retinopathy, corneal opacity sufficient to impair surgical view, premenopausal status (potential teratogenic risk) or previous vitrectomy (Asaria 2001).

Types of interventions

We considered the following interventions:

1. Intravitreal LMWH (added to vitrectomy infusion fluid).
2. Adjuvant intravitreal LMWH and 5-FU (added to vitrectomy infusion fluid).
3. Placebo (control group) - normal vitrectomy infusion fluid (balanced salt solution).

Types of outcome measures

Primary outcomes

The development of postoperative PVR. This was determined at follow-up visits with complete retinal examination within six months postoperatively. The presence or absence of PVR and the reattachment status of the retina were recorded. Definitions and grading of PVR may vary in the included trials. We recorded the variations in the definitions and noted whether the outcome was measured using a validated technique in the ‘Characteristics of included studies’ table.

The gold standard for defining and grading PVR is the new adaptation of the Retinal Society Classification described by the Silicone Study Group (Lean 1989). The 1983 Retina Society classification was modified in 1989 by the Silicone Study Group, whose classification differentiates between posterior and anterior forms of PVR and recognises three patterns of proliferation: diffuse, focal and subretinal.

Secondary outcomes

Reoperation rate and change in visual acuity within six months postoperatively.

Adverse effects (severe, minor)

Intraoperative ocular haemorrhage, postoperative ocular haemorrhage and retinal redetachment rate.
Economic data
The cost of combined LMWH and 5-FU is $6.00 (Asaria 2001).

Search methods for identification of studies

Electronic searches
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2010, Issue 5), MEDLINE (January 1950 to May 2010), EMBASE (January 1980 to May 2010), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) and ClinicalTrials.gov (http://clinicaltrials.gov). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 24 May 2010. See: Appendices for details of search strategies for CENTRAL (Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix 3), mRCT (Appendix 4) and ClinicalTrials.gov (Appendix 5).

Searching other resources
The lead author searched the reference lists of the studies included in the review for information about further trials. We did not handsearch journals or conference proceedings specifically for the review.

Data collection and analysis

Selection of studies
Two authors, working independently, assessed the titles and abstracts resulting from the searches. The full copy of all possibly or definitely relevant studies were obtained for further assessment. Both authors assessed these full copies to see if they did indeed meet the inclusion criteria. The lead author contacted study authors for clarification of any details necessary in order to make a complete assessment of the relevance of a study.

Data extraction and management
We extracted data from each study, ensuring that the patients met the criteria described above under participants, and looked at the outcome measures described above. We looked at dichotomous data for the primary outcomes and at continuous data for the secondary outcomes listed above. The unit of analysis was an individual person.

Data were entered into RevMan 5 by two authors working independently and checked in RevMan 5. We approached the trial authors for information on missing data or where data were difficult to determine from the full copy of the paper. We extracted the following study characteristics from each study included:
1. Methods: method of allocation, masking (participant, provider, outcome), exclusions after randomisation, losses to follow-up and compliance, unusual study design.
2. Participants: country where participants enrolled, number randomised, age, sex, main inclusion and exclusion criteria.
3. Interventions: treatment, comparison intervention (control), duration of intervention.
4. Outcomes: relevant outcomes on which data were collected in the trial and length of follow-up.
5. Notes: additional details relevant to that particular trial (e.g. funding sources).

Assessment of risk of bias in included studies
We assessed all full copies for inclusion in the review for methodological quality according to Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 (Higgins 2009). We considered five parameters of quality:
1. Randomisation sequence generation
2. Allocation concealment
3. Masking of surgeon and patients
4. Incomplete outcome data
5. Selective reporting
We assessed each parameter of trial quality and graded it as yes (low risk of bias), no (high risk of bias) or unclear.

Measures of treatment effect
For dichotomous outcomes we calculated a summary relative risk. We calculated a mean difference for continuous outcomes. We will calculate a standardized mean difference if different scales are used to measure continuous outcomes in studies found when updating this review (Deeks 2009).

Unit of analysis issues
We did not expect such an issue to be found because these intervention are generally unilateral.

Dealing with missing data
When there were missing data in a study, unless causes of missingness could not be associated to treatment allocation such as death or patient refused surgery, we used Stata software 11.0 metamiss macro (White 2008) to explore the impact of missing data assuming fixed and opposite informative missing odds ratio (IMOR) 2 or 1/2.
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery (Review)  
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
a protocol violation and these patients were included for analysis. The number of protocol violations was similar between the two groups (N=15 in the treatment group and N=18 in the placebo group), so this is unlikely to have caused significant bias.

In Asaria 2001, if the operation lasted for more than one hour the infusion bag was replaced with a new identical infusion, whereas in Wickham 2007, the infusion bag was replaced with Hartmann solution irrespective of the group.

All patients underwent standard three-port pars plana vitrectomy, with retinopexy using endolaser, indirect laser or cryotherapy where appropriate. Internal tamponade was achieved with either perfluoropropane (C3F8) gas or sulphur hexafluoride (SF6) gas. Silicone oil was used when indicated in Asaria 2001.

**Types of outcome measures**

In Asaria 2001, the primary outcome measure was postoperative PVR, defined as PVR greater than CP1 according to the new Retinal Society Classification. Secondary outcome measures were reoperation rate, change in visual acuity and complication rates. Treatment success was defined as complete retinal reattachment and no reoperations within six months.

In Wickham 2007, the primary outcome measure was retinal reattachment after primary vitrectomy without reoperation at six months. Secondary outcome measures were occurrence and grade of PVR (grade C and above), best corrected visual acuity, intraocular pressure, corneal clarity and complications.

**Excluded studies**

We excluded two studies. One study (Wang 2006) appeared to meet our inclusion criteria from the abstract. The rest of the study was published in Chinese. We contacted Dr. Wang Yong directly who confirmed that the study was not an RCT and so was excluded from the review. The second study, Scheer 2005 was rejected after reviewing the full copy as it was not an RCT. See the 'Characteristics of excluded studies' table for further details.

**Risk of bias in included studies**

See Figure 1.

---

**Figure 1. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.**
**Allocation**
In both studies, randomisation was carried out after patients had been scheduled for surgery and recruited and was performed with the help of a medical statistics support office. A randomisation schedule was used by the pharmacy department who then dispensed coded vials of treatment drugs or placebo.

**Blinding**
In both studies, the patients and surgeons were masked (blinded) to the type of infusion fluid being used.

**Incomplete outcome data**
In both studies data were analysed according to the group to which patients were assigned (i.e. on an intention-to-treat basis).

In **Asaria 2001**, data for 5/87 patients in the placebo group and 2/87 patients in the treatment group were missing at three and six month follow up examinations. A simulation on these data as described in the 'Data collection and analysis’ section did not substantially change the results.

In **Wickham 2007**, six month follow up data was incomplete for 15/342 patients in the treatment group and 11/299 patients in the placebo group. We suggest there is no need to carry out simulations on the impact of missing data since the loss was balanced and its causes were also similar and unlikely to be related to treatment outcome (surgery cancelled or patient did not attend or withdrew consent, death).

**Selective reporting**
The primary outcome of this review was reported by both studies included in this review using the same definition. Re-operation rates were also reported. Visual acuity change was defined differently in the two studies: **Asaria 2001** used a three-level categorisation (worse, stable, better), while **Wickham 2007** reported continuous logMAR visual acuity as median and interquartile range. Thus, there is potential selective reporting, but only regarding this secondary outcome in our review.

We could not investigate publication bias due to the fact that only two studies are included in the review.

**Effects of interventions**

**5-Fluorouracil and LWMH versus placebo**

**Primary outcome: postoperative PVR**

We did not perform a meta-analysis since **Asaria 2001** and **Wickham 2007** yielded estimates of effect in the opposite direction which were heterogeneous (Chi² test for heterogeneity P = 0.02 and I² 82% in **Analysis 1.1**). Only **Asaria 2001** yielded a statistical significant difference favouring LMWH with 5-FU.

**Secondary outcomes:**

1. **Reoperation rates**
High heterogeneity between **Asaria 2001** and **Wickham 2007** was also seen for reoperation rates (Chi² test for heterogeneity P = 0.08 and I² 67% in **Analysis 1.2**), but in this case neither study yielded a statistically significant difference between the two groups.

2. **Change in visual acuity**
The two included studies reported visual acuity differently. We could extract the proportion of people in whom visual acuity had worsened at the last examination from **Asaria 2001**, and the comparison favoured LMWH with 5-FU (**Analysis 1.3**).

In **Wickham 2007**, data were presented as median and interquartile range (IQR). Since there was little evidence of skewness (i.e. the median was roughly centred in the IQR), we used it to approximate means and we used IQR as an estimate of standard deviation (times 1.35 as suggested in **Higgins 2009**). After such data manipulation we could not show a difference between LMWH with 5-FU and placebo (**Analysis 1.4**).

3. **Complications**
In **Asaria 2001**, five patients developed postoperative hyphaema in each group, all of which were mild and settled with conservative treatment. One retinal incarceration and one choroidal haemorrhage occurred in the treatment group.

In **Wickham 2007**, choroidal haemorrhage occurred in one patient in both the placebo and treatment groups. Two patients had retinal incarceration in the treatment group.

**DISCUSSION**

**Summary of main results**
Although two trials were included in this review, we did not perform meta-analysis because of statistical heterogeneity between the
trials for both the primary and the secondary anatomic outcome. This is further substantiated by clinical heterogeneity due to inclusion criteria leading to very different preoperative risk of developing postoperative PVR. Such different inclusion criteria lead to different rates of PVR in the control group of each study (26% for Asaria 2001 and 5% for Wickham 2007). The fact that only Asaria 2001 found LMWH with 5-FU beneficial to prevent postoperative PVR could be ascribed to an interaction of treatment with baseline risk, i.e. the control event rate. The rationale for this difference would be that LMWH with 5-FU infusion would only be effective in preventing postoperative PVR in patients undergoing primary vitrectomy for rhegmatogenous retinal detachment who were viewed at high-risk of developing postoperative PVR, whereas in cases of rhegmatogenous retinal detachment at low risk of PVR development its use might be associated with a worse visual outcome in macular sparing detachments as there are concerns about the use of a cytotoxic agent in a continuous infusion such as 5-FU.

However, the hypothesis of an interaction between baseline risk and treatment effect cannot be tested formally in subgroup analysis in our review with only two included studies, so this explanation remains presumptive.

**Overall completeness and applicability of evidence**

The heterogeneous results of the two studies regarding the direction of the effect for the primary outcome may suggest that heterogeneity is to be expected in studies on the use of LMWH and 5-FU to prevent PVR during vitrectomy. This is in agreement with the fact that this is a complex surgical procedure which can be applied to very different patients. Thus, the evidence collected in this review is largely incomplete and insufficient to guide clinical practice.

**Quality of the evidence**

**References to studies included in this review**

Asaria 2001  *(published data only)*

Wickham 2007  *(published data only)*

**References to studies excluded from this review**

Scheer 2005  *(published data only)*
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
van Bockxmeer 1985

Verstraeten 1992

White 2008

Wiedemann 1987

Wiedemann 1991

* Indicates the major publication for the study
# Characteristics of Studies

**Characteristics of included studies** *(ordered by study ID)*

**Asaria 2001**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Double masked, prospective, randomised, placebo-controlled clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>174 participants with rhegmatogenous retinal detachment who were also viewed at high-risk of developing postoperative PVR, undergoing primary vitrectomy</td>
</tr>
<tr>
<td>Interventions</td>
<td>Treatment group received a continuous intraocular LMWH and 5-FU infusion. Placebo group received normal saline infusion</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Treatment group had significantly lower postoperative PVR rates</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>Randomisation was carried out after the patient had been scheduled for surgery and recruited. Randomisation was performed with the help of the medical statistics support office, and a randomisation schedule was sent to the pharmacy department, which dispensed coded vials of treatment drugs or placebo</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>Coded vials of treatment or placebo were added to infusion bag just prior to surgery</td>
</tr>
<tr>
<td>Blinding? Participants</td>
<td>Yes</td>
<td>Participants masked (blinded) throughout study and treatment allocation only revealed at end of study</td>
</tr>
<tr>
<td>Blinding? Surgeons</td>
<td>Yes</td>
<td>Surgeons masked throughout study and treatment allocation only revealed at end of study</td>
</tr>
<tr>
<td>Incomplete outcome data addressed? All outcomes</td>
<td>Yes</td>
<td>Follow-up good and similar between both groups. 94.3% of participants in the placebo group and 97.7% of participants in the treatment group completed the six month follow-up visit</td>
</tr>
</tbody>
</table>
Free of selective reporting? | Yes
---|---
Selective reporting is not an issue for the primary outcome "development of PVR", or the secondary outcome "reoperation rate". It may be an outcome only for the secondary outcome "visual acuity" as this is a more subjective assessment and was defined differently in both included studies.

### Wickham 2007

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Double masked, prospective, randomised, placebo-controlled clinical trial</td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>641 participants with rhegmatogenous retinal detachments from two specialist vitreo-retinal units, with all participants undergoing primary vitrectomy</td>
<td></td>
</tr>
<tr>
<td>Interventions</td>
<td>Treatment group received a continuous intraocular LMWH and 5-FU infusion. Placebo group received normal saline infusion</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td>No significant difference in PVR rates between the two groups. Macular sparring detachments who received the LMWH and 5-FU infusion had a significantly worse visual acuity</td>
<td></td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>After recruitment, non-trial personnel randomised participants on the day of surgery to the treatment or placebo groups using a computer generated weighted coin method</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>Randomisation code kept on separate computer from investigators and pre-prepared coded infusion fluid used</td>
</tr>
<tr>
<td>Blinding? Participants</td>
<td>Yes</td>
<td>Participants masked throughout and treatment allocation only revealed at end of study</td>
</tr>
<tr>
<td>Blinding? Surgeons</td>
<td>Yes</td>
<td>Surgeons masked throughout and treatment allocation only revealed at end of study</td>
</tr>
<tr>
<td>Incomplete outcome data addressed? All outcomes</td>
<td>Yes</td>
<td>Follow-up good and similar between both groups, 96.3% of participants in the...</td>
</tr>
</tbody>
</table>
placebo group and 95.6% of participants in the treatment group completed the six month follow-up visit. Causes were also similar in the two groups and also unlikely to be related to treatment outcome (surgery cancelled, participant did not attend or withdrew consent, death)

Free of selective reporting? Yes

Selective reporting is not an issue for the primary outcome "development of PVR", or the secondary outcome "reoperation rate". It may be an outcome only for the secondary outcome "visual acuity" as this is a more subjective assessment and was defined differently in both included studies.

5-FU: 5-Fluorouracil
LMWH: low molecular weight heparin
PVR: proliferative vitreoretinopathy

Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scheer 2005</td>
<td>Not a randomised controlled trial.</td>
</tr>
<tr>
<td>Wang 2006</td>
<td>Not a randomised controlled trial.</td>
</tr>
</tbody>
</table>